{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:38:19Z","timestamp":1791581899154,"version":"4.3.4"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["11941-2018-II"],"award-info":[{"award-number":["11941-2018-II"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.canlet.2022.215804","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T22:01:13Z","timestamp":1655848873000},"page":"215804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Mechanisms used by cancer cells to tolerate drug-induced replication stress"],"prefix":"10.1016","volume":"544","author":[{"given":"Hendrika A.","family":"Segeren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1043-3638","authenticated-orcid":false,"given":"Bart","family":"Westendorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2022.215804_bib1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-pathol-012414-040424","article-title":"DNA replication stress as a hallmark of cancer","volume":"10","author":"Macheret","year":"2015","journal-title":"Annu. Rev. Pathol."},{"issue":"5","key":"10.1016\/j.canlet.2022.215804_bib2","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.trecan.2020.10.010","article-title":"Beyond kinases: targeting replication stress proteins in cancer therapy","volume":"7","author":"Baillie","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.canlet.2022.215804_bib3","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1038\/onc.2012.387","article-title":"Increased replication initiation and conflicts with transcription underlie Cyclin E-induced replication stress","volume":"32","author":"Jones","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2022.215804_bib4","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.celrep.2013.04.002","article-title":"Cdc45 is a critical effector of myc-dependent DNA replication stress","volume":"3","author":"Srinivasan","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2022.215804_bib5","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature25507","article-title":"Intragenic origins due to short G1 phases underlie oncogene-induced DNA replication stress","volume":"555","author":"Macheret","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2022.215804_bib6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.cell.2011.03.044","article-title":"Nucleotide deficiency promotes genomic instability in early stages of cancer development","volume":"145","author":"Bester","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2022.215804_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13087","article-title":"Increased global transcription activity as a mechanism of replication stress in cancer","volume":"7","author":"Kotsantis","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2022.215804_bib8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cell.2012.08.026","article-title":"Transcriptional amplification in tumor cells with elevated c-Myc","volume":"151","author":"Lin","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2022.215804_bib9","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature10189","article-title":"Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis","volume":"475","author":"DeNicola","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2022.215804_bib10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/ncb1882","article-title":"Replication stress induces sister-chromatid bridging at fragile site loci in mitosis","volume":"11","author":"Chan","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2022.215804_bib11","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrm.2017.67","article-title":"The essential kinase ATR: ensuring faithful duplication of a challenging genome","volume":"18","author":"Saldivar","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2022.215804_bib12","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.cels.2017.09.015","article-title":"Orchestration of DNA damage checkpoint dynamics across the human cell cycle","volume":"5","author":"Chao","year":"2017","journal-title":"Cell Syst."},{"key":"10.1016\/j.canlet.2022.215804_bib13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.molcel.2016.03.006","article-title":"A genome-wide CRISPR screen identifies CDC25A as a determinant of sensitivity to ATR inhibitors","volume":"62","author":"Ruiz","year":"2016","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2022.215804_bib14","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/nsmb.2189","article-title":"Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors","volume":"18","author":"Murga","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.canlet.2022.215804_bib15","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1158\/1078-0432.CCR-17-2701","article-title":"Endogenous replication stress marks melanomas sensitive to CHEK1 inhibitors in vivo","volume":"24","author":"Oo","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2022.215804_bib16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1172\/JCI58928","article-title":"Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR","volume":"122","author":"Schoppy","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2022.215804_bib17","doi-asserted-by":"crossref","first-page":"9693","DOI":"10.1158\/0008-5472.CAN-10-2286","article-title":"Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner","volume":"70","author":"Gilad","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.215804_bib18","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nsmb.2076","article-title":"A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations","volume":"18","author":"Toledo","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.canlet.2022.215804_bib19","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.molcel.2015.07.029","article-title":"Distinct but concerted roles of ATR, DNA-PK, and Chk1 in countering replication stress during S phase","volume":"59","author":"Buisson","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2022.215804_bib20","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.cell.2013.10.043","article-title":"ATR prohibits replication catastrophe by preventing global exhaustion of RPA","volume":"155","author":"Toledo","year":"2013","journal-title":"Cell (Cambridge)"},{"key":"10.1016\/j.canlet.2022.215804_bib21","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/s41467-020-15308-7","article-title":"Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer","volume":"11","author":"Li","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2022.215804_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-07472-8","article-title":"Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis","volume":"9","author":"Santana-Codina","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2022.215804_bib23","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1101\/gad.256958.114","article-title":"Increased Rrm2 gene dosage reduces fragile site breakage and prolongs survival of ATR mutant mice","volume":"29","author":"Lopez-Contreras","year":"2015","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2022.215804_bib24","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/sj.onc.1207272","article-title":"RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine","volume":"23","author":"Duxbury","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2022.215804_bib25","doi-asserted-by":"crossref","first-page":"e3695","DOI":"10.1371\/journal.pone.0003695","article-title":"Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients","volume":"3","author":"Boukovinas","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2022.215804_bib26","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/onc.2014.155","article-title":"Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies","volume":"34","author":"Aye","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2022.215804_bib27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature12040","article-title":"Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway","volume":"496","author":"Son","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2022.215804_bib28","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1158\/0008-5472.CAN-19-1363","article-title":"Undermining glutaminolysis bolsters chemotherapy while NRF2 promotes chemoresistance in KRAS-driven pancreatic cancers","volume":"80","author":"Mukhopadhyay","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.215804_bib29","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ccell.2017.06.004","article-title":"MUC1 and HIF-1alpha signaling Crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer","volume":"32","author":"Shukla","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2022.215804_bib30","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1158\/0008-5472.CAN-18-0618","article-title":"Replication protein A availability during DNA replication stress is a major determinant of cisplatin resistance in ovarian cancer cells","volume":"78","author":"B\u00e9langer","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.215804_bib31","doi-asserted-by":"crossref","first-page":"8898","DOI":"10.1093\/nar\/gky657","article-title":"Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells","volume":"46","author":"Clements","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2022.215804_bib32","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.molcel.2017.06.023","article-title":"RADX promotes genome stability and modulates chemosensitivity by regulating RAD51 at replication forks","volume":"67","author":"Dungrawala","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2022.215804_bib33","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.molcel.2017.09.036","article-title":"Restoration of replication fork stability in BRCA1- and BRCA2-deficient cells by inactivation of SNF2-family fork remodelers","volume":"68","author":"Taglialatela","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2022.215804_bib34","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature18325","article-title":"Replication fork stability confers chemoresistance in BRCA-deficient cells","volume":"535","author":"Ray Chaudhuri","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2022.215804_bib35","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.molcel.2019.10.008","article-title":"PRIMPOL-mediated adaptive response suppresses replication fork reversal in BRCA-deficient cells","volume":"77","author":"Quinet","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2022.215804_bib36","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41467-019-08886-8","article-title":"Overexpression of Claspin and Timeless protects cancer cells from replication stress in a checkpoint-independent manner","volume":"10","author":"Bianco","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2022.215804_bib37","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/1476-4598-13-211","article-title":"TopBP1 and Claspin contribute to the radioresistance of lung cancer brain metastases","volume":"13","author":"Choi","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2022.215804_bib38","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1038\/oncsis.2012.29","article-title":"DNA replication stress response involving PLK1, CDC6, POLQ, RAD51 and CLASPIN upregulation prognoses the outcome of early\/mid-stage non-small cell lung cancer patients","volume":"1","author":"Allera-Moreau","year":"2012","journal-title":"Oncogenesis"},{"key":"10.1016\/j.canlet.2022.215804_bib39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bpc.2016.11.005","article-title":"Distinct functions of human RecQ helicases during DNA replication","volume":"225","author":"Urban","year":"2017","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.canlet.2022.215804_bib40","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1038\/leu.2017.54","article-title":"RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma","volume":"31","author":"Viziteu","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2022.215804_bib41","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.mrfmmm.2015.03.001","article-title":"WRN translocation from nucleolus to nucleoplasm is regulated by SIRT1 and required for DNA repair and the development of chemoresistance","volume":"774","author":"Lee","year":"2015","journal-title":"Mutat. Res."},{"key":"10.1016\/j.canlet.2022.215804_bib42","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1158\/0008-5472.CAN-15-2361","article-title":"Human helicase RECQL4 drives cisplatin resistance in gastric cancer by activating an AKT-YB1-MDR1 signaling pathway","volume":"76","author":"Mo","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.215804_bib43","doi-asserted-by":"crossref","first-page":"76140","DOI":"10.18632\/oncotarget.12683","article-title":"Altered RECQL5 expression in urothelial bladder carcinoma increases cellular proliferation and makes RECQL5 helicase activity a novel target for chemotherapy","volume":"7","author":"Patterson","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2022.215804_bib44","first-page":"347","volume":"vol. 20","author":"Berti","year":"2013"},{"key":"10.1016\/j.canlet.2022.215804_bib45","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nsmb1267","article-title":"Role for BLM in replication-fork restart and suppression of origin firing after replicative stress","volume":"14","author":"Davies","year":"2007","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.canlet.2022.215804_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12880","article-title":"CDK1 phosphorylates WRN at collapsed replication forks","volume":"7","author":"Palermo","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2022.215804_bib47","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1158\/0008-5472.CAN-15-1884","article-title":"The error-prone DNA polymerase \u03ba promotes temozolomide resistance in glioblastoma through Rad17-dependent activation of ATR-Chk1 signaling","volume":"76","author":"Peng","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.215804_bib48","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1111\/j.1349-7006.2012.02309.x","article-title":"Overexpression of DNA polymerase iota (Pol\u03b9) in esophageal squamous cell carcinoma","volume":"103","author":"Zhou","year":"2012","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2022.215804_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083978","article-title":"Expression of DNA translesion synthesis polymerase \u03b7 in head and neck squamous cell cancer predicts resistance to gemcitabine and cisplatin-based chemotherapy","volume":"8","author":"Zhou","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2022.215804_bib50","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/cas.12390","article-title":"Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells","volume":"105","author":"Niimi","year":"2014","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2022.215804_bib51","doi-asserted-by":"crossref","first-page":"4411","DOI":"10.1073\/pnas.1421365112","article-title":"Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells","volume":"112","author":"Srivastava","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2022.215804_bib52","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1158\/0008-5472.CAN-14-0953","article-title":"Translesion polymerase \u03b7 is upregulated by cancer therapeutics and confers anticancer drug resistance","volume":"74","author":"Tomicic","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.215804_bib53","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1158\/0008-5472.CAN-04-0603","article-title":"Altered DNA polymerase \u03b9 expression in breast cancer cells leads to a reduction in DNA replication fidelity and a higher rate of mutagenesis","volume":"64","author":"Yang","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.215804_bib54","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cell.2019.05.028","article-title":"A small molecule targeting mutagenic translesion synthesis improves chemotherapy","volume":"178","author":"Wojtaszek","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2022.215804_bib55","doi-asserted-by":"crossref","first-page":"28922","DOI":"10.1073\/pnas.2016067117","article-title":"Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer","volume":"117","author":"Vassel","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2022.215804_bib56","doi-asserted-by":"crossref","first-page":"20786","DOI":"10.1073\/pnas.1011409107","article-title":"Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy","volume":"107","author":"Doles","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2022.215804_bib57","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/nsmb.2719","article-title":"Repriming of DNA synthesis at stalled replication forks by human PrimPol","volume":"20","author":"Mour\u00f3n","year":"2013","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.canlet.2022.215804_bib58","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1101\/gad.457807","article-title":"Dormant origins licensed by excess Mcm2\u20137 are required for human cells to survive replicative stress","volume":"21","author":"Ge","year":"2007","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2022.215804_bib59","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.celrep.2017.01.072","article-title":"Targeting DNA damage response in prostate cancer by inhibiting androgen receptor-CDC6-ATR-chk1 signaling","volume":"18","author":"Karanika","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2022.215804_bib60","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.tibs.2019.03.011","article-title":"Replication licensing aberrations, replication stress, and genomic instability","volume":"44","author":"Petropoulos","year":"2019","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.canlet.2022.215804_bib61","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.cell.2005.08.013","article-title":"CDKs promote DNA replication origin licensing in human cells by protecting Cdc6 from APC\/C-dependent proteolysis","volume":"122","author":"Mailand","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2022.215804_bib62","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/1541-7786.MCR-12-0491","article-title":"Diminished origin-licensing capacity specifically sensitizes tumor cells to replication stress","volume":"11","author":"Zimmerman","year":"2013","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2022.215804_bib63","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1158\/1541-7786.MCR-14-0464","article-title":"Suppression of reserve MCM complexes chemosensitizes to gemcitabine and 5-fluorouracil","volume":"13","author":"Bryant","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2022.215804_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009176","article-title":"Dual genome-wide CRISPR knockout and CRISPR activation screens identify mechanisms that regulate the resistance to multiple ATR inhibitors","volume":"16","author":"Schleicher","year":"2020","journal-title":"PLoS Genet."},{"key":"10.1016\/j.canlet.2022.215804_bib65","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1084\/jem.20112147","article-title":"An extra allele of Chk1 limits oncogene-induced replicative stress and promotes transformation","volume":"209","author":"L\u00f3pez-Contreras","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2022.215804_bib66","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.51963","article-title":"The evolutionary plasticity of chromosome metabolism allows adaptation to constitutive DNA replication stress","volume":"9","author":"Fumasoni","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.canlet.2022.215804_bib67","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1158\/1535-7163.MCT-13-0157","article-title":"Chk1\/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53","volume":"12","author":"Gadhikar","year":"2013","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2022.215804_bib68","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/s41388-021-02141-5","article-title":"p53 partial loss-of-function mutations sensitize to chemotherapy","volume":"41","author":"Klimovich","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2022.215804_bib69","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1172\/JCI58765","article-title":"Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models","volume":"122","author":"Ma","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2022.215804_bib70","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1038\/s41388-022-02291-0","article-title":"Oncogenic RAS sensitizes cells to drug-induced replication stress via transcriptional silencing of P53","volume":"41","author":"Segeren","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2022.215804_bib71","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.devcel.2020.01.024","article-title":"WAPL-dependent repair of damaged DNA replication forks underlies oncogene-induced loss of sister chromatid cohesion","volume":"52","author":"Benedict","year":"2020","journal-title":"Dev. Cell"},{"key":"10.1016\/j.canlet.2022.215804_bib72","doi-asserted-by":"crossref","first-page":"R9","DOI":"10.1186\/bcr2814","article-title":"Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers","volume":"13","author":"Xu","year":"2011","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2022.215804_bib73","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1101\/gad.345454.120","article-title":"RAD21 is a driver of chromosome 8 gain in Ewing sarcoma to mitigate replication stress","volume":"35","author":"Su","year":"2021","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2022.215804_bib74","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1038\/onc.2016.502","article-title":"Census and evaluation of p53 target genes","volume":"36","author":"Fischer","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2022.215804_bib75","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","article-title":"ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells","volume":"127","author":"Kwok","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2022.215804_bib76","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature22794","article-title":"Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance","volume":"546","author":"Shaffer","year":"2017","journal-title":"Nature (London)"},{"issue":"1","key":"10.1016\/j.canlet.2022.215804_bib77","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/hep.31259","article-title":"E2F7 is a potent inhibitor of liver tumor growth in adult mice","volume":"73","author":"Moreno","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2022.215804_bib78","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/onc.2013.529","article-title":"SALL4 is a new target in endometrial cancer","volume":"34","author":"Li","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2022.215804_bib79","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.celrep.2016.04.036","article-title":"Sustained E2F-dependent transcription is a key mechanism to prevent replication-stress-induced DNA damage","volume":"15","author":"Bertoli","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2022.215804_bib80","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1093\/nar\/gkr1203","article-title":"E2F7 represses a network of oscillating cell cycle genes to control S-phase progression","volume":"40","author":"Westendorp","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2022.215804_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108449","article-title":"Excessive E2F transcription in single cancer cells precludes transient cell-cycle exit after DNA damage","volume":"33","author":"Segeren","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2022.215804_bib82","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.cub.2013.06.063","article-title":"Chk1 inhibits E2F6 repressor function in response to replication stress to maintain cell-cycle transcription","volume":"23","author":"Bertoli","year":"2013","journal-title":"Curr. Biol."},{"key":"10.1016\/j.canlet.2022.215804_bib83","doi-asserted-by":"crossref","DOI":"10.15252\/embj.201797877","article-title":"Chk1 and 14-3-3 proteins inhibit atypical E2Fs to prevent a permanent cell cycle arrest","volume":"37","author":"Yuan","year":"2018","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2022.215804_bib84","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1128\/MCB.00938-09","article-title":"E2F3 is a mediator of DNA damage-induced apoptosis","volume":"30","author":"Martinez","year":"2010","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2022.215804_bib85","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2018101430","article-title":"Cyclin F-dependent degradation of E2F7 is critical for DNA repair and G2-phase progression","volume":"38","author":"Yuan","year":"2019","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2022.215804_bib86","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.molcel.2019.04.010","article-title":"Cyclin F controls cell-cycle transcriptional outputs by directing the degradation of the three activator E2Fs","volume":"74","author":"Clijsters","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2022.215804_bib87","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2018101443","article-title":"E2F1 proteolysis via SCF-cyclin F underlies synthetic lethality between cyclin F loss and Chk1 inhibition","volume":"38","author":"Burdova","year":"2019","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2022.215804_bib88","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.cell.2012.03.043","article-title":"Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair","volume":"149","author":"D'Angiolella","year":"2012","journal-title":"Cell (Cambridge)"},{"key":"10.1016\/j.canlet.2022.215804_bib89","doi-asserted-by":"crossref","first-page":"216","DOI":"10.18632\/oncotarget.27400","article-title":"A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib","volume":"11","author":"Blosser","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2022.215804_bib90","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar7223","article-title":"Targeting the XPO1-dependent nuclear export of E2F7 reverses anthracycline resistance in head and neck squamous cell carcinomas","volume":"10","author":"Saenz-Ponce","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2022.215804_bib91","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nrc2696","article-title":"Emerging roles of E2Fs in cancer: an exit from cell cycle control","volume":"9","author":"Leone","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2022.215804_bib92","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ccr.2012.05.016","article-title":"Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming","volume":"22","author":"Mitsuishi","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2022.215804_bib93","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/ng.3421","article-title":"NRF2 regulates serine biosynthesis in non\u2013small cell lung cancer","volume":"47","author":"DeNicola","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2022.215804_bib94","doi-asserted-by":"crossref","first-page":"9109","DOI":"10.1093\/nar\/gkaa631","article-title":"NRF2 preserves genomic integrity by facilitating ATR activation and G2 cell cycle arrest","volume":"48","author":"Sun","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2022.215804_bib95","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1158\/0008-5472.CAN-10-0713","article-title":"High levels of Nrf2 determine chemoresistance in type II endometrial cancer","volume":"70","author":"Jiang","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.215804_bib96","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/nm.4407","article-title":"Keap1 loss promotes Kras -driven lung cancer and results in dependence on glutaminolysis","volume":"23","author":"Romero","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2022.215804_bib97","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/0008-5472.CAN-12-3227","article-title":"CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma","volume":"73","author":"Ooi","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.215804_bib98","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1053\/j.gastro.2008.06.082","article-title":"Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer","volume":"135","author":"Shibata","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2022.215804_bib99","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1158\/1078-0432.CCR-17-1841","article-title":"Effects of Co-occurring genomic alterations on outcomes in patients with KRAS-mutant non\u2013small cell lung cancer","volume":"24","author":"Arbour","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2022.215804_bib100","doi-asserted-by":"crossref","DOI":"10.3390\/cells9071643","article-title":"The E2F pathway score as a predictive biomarker of response to neoadjuvant therapy in ER+\/HER2- breast cancer","volume":"9","author":"Oshi","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2022.215804_bib101","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2022.215804_bib102","article-title":"Bladder cancer","volume":"3","author":"Sanli","year":"2017","journal-title":"Nature Rev. Dis. Primer"},{"key":"10.1016\/j.canlet.2022.215804_bib103","first-page":"1133","article-title":"Integrated analysis of the E2F transcription factors across cancer types","volume":"43","author":"Wang","year":"2020","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2022.215804_bib104","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Neuvial","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2022.215804_bib105","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(20)32554-X","article-title":"Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Lheureux","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.canlet.2022.215804_bib106","doi-asserted-by":"crossref","first-page":"eaaaz7808","DOI":"10.1126\/sciadv.aaz7808","article-title":"Inhibition of the translesion synthesis polymerase REV1 exploits replication gaps as a cancer vulnerability","volume":"10","author":"Nayak","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2022.215804_bib107","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1146\/annurev-pharmtox-052220-104025","article-title":"Targeting NRF2 and its downstream processes: opportunities and challenges","volume":"62","author":"Torrente","year":"2022","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.canlet.2022.215804_bib108","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting Chimeras (PROTACs) \u2014 past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.canlet.2022.215804_bib109","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1093\/nar\/gkw523","article-title":"Integration of TP53, DREAM, MMB-FOXM1 and RB-E2F target gene analyses identifies cell cycle gene regulatory networks","volume":"44","author":"Fischer","year":"2016","journal-title":"Nucleic Acids Res."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383522002889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383522002889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:04:02Z","timestamp":1759593842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383522002889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":109,"alternative-id":["S0304383522002889"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2022.215804","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms used by cancer cells to tolerate drug-induced replication stress","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2022.215804","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"215804"}}